Literature DB >> 9355789

Alterations of the phenotype of colonic macrophages in inflammatory bowel disease.

G Rogler1, T Andus, E Aschenbrenner, D Vogl, W Falk, J Schölmerich, V Gross.   

Abstract

BACKGROUND: Intestinal macrophages play an important role in mucosal inflammation. In normal colonic mucosa we recently demonstrated a unique macrophage phenotype with attenuated immune functions. Here we present an analysis of the alterations of the phenotype of colonic macrophages in inflammatory bowel disease (IBD).
METHODS: Intestinal macrophages were isolated from biopsies of patients with IBD (n =20). Flow cytometric triple fluorescence analysis was applied to study CD14, CD16, CD33, HLA-DR, CD44, CD11b, CD11c and CD3/CD19 expression.
RESULTS: In IBD there was an increase in expression not only of CD14 compared to control mucosa (36.0% +/- 13.2% vs. 10.5% +/- 3.8%, P< 0.0001) but also of CD16 (28.6% +/- 10.3% vs. 10.1% +/- 3.9%, P< 0.0001), HLA-DR (53.1% +/- 15.9% vs. 27.3% +/- 9.2%, P< 0.0005), CD11b (42.8% +/- 14.2% vs. 17.4% +/- 6.8%, P< 0.0001) and CD11c (35.1% +/- 15.9% vs. 17.8% +/- 10.4%, P< 0.005.). Furthermore, a hitherto undescribed new population of macrophages could be detected by flow cytometry only in patients with ulcerative colitis (CD16++, CD11b++, CD14(low), CD33(low), CD11c-) accounting for 5.8% of all cells isolated.
CONCLUSION: In contrast to colonic macrophages from normal mucosa, there is a significantly higher expression of CD14, CD16, HLA-DR, CD11b and CD11c in IBD, indicating additional macrophage populations in the inflamed mucosa. This may reflect either a recruitment of new cells from the circulation or a change in phenotype of resident cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355789     DOI: 10.1097/00042737-199709000-00013

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  21 in total

1.  Role of soluble factors and three-dimensional culture in in vitro differentiation of intestinal macrophages.

Authors:  Tanja Spoettl; Martin Hausmann; Katrin Menzel; Heidi Piberger; Hans Herfarth; Juergen Schoelmerich; Frauke Bataille; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes.

Authors:  T Spoettl; M Hausmann; M Herlyn; M Gunckel; A Dirmeier; W Falk; H Herfarth; J Schoelmerich; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

Review 4.  Intestinal macrophages: differentiation and involvement in intestinal immunopathologies.

Authors:  Benjamin Weber; Leslie Saurer; Christoph Mueller
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

5.  Matrix-Bound Nanovesicles Recapitulate Extracellular Matrix Effects on Macrophage Phenotype.

Authors:  Luai Huleihel; Joseph G Bartolacci; Jenna L Dziki; Tatiana Vorobyov; Brooke Arnold; Michelle E Scarritt; Catalina Pineda Molina; Samuel T LoPresti; Bryan N Brown; Juan Diego Naranjo; Stephen F Badylak
Journal:  Tissue Eng Part A       Date:  2017-06-30       Impact factor: 3.845

6.  Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages.

Authors:  M Hausmann; T Spöttl; T Andus; G Rothe; W Falk; J Schölmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

7.  Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?

Authors:  Lenka Frol'ová; Karel Smetana; Dana Borovská; Andrea Kitanovicová; Klára Klimesová; Ivana Janatková; Karin Malícková; Milan Lukás; Pavel Drastich; Zdenek Benes; Ludmila Tucková; Joachim C Manning; Sabine André; Hans-Joachim Gabius; Helena Tlaskalová-Hogenová
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

8.  The GPR55 antagonist CID16020046 protects against intestinal inflammation.

Authors:  A Stančić; K Jandl; C Hasenöhrl; F Reichmann; G Marsche; R Schuligoi; A Heinemann; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 3.598

9.  TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases.

Authors:  Mirjam Schenk; Axel Bouchon; Frank Seibold; Christoph Mueller
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis.

Authors:  Lenka Frolova; Pavel Drastich; Pavel Rossmann; Klara Klimesova; Helena Tlaskalova-Hogenova
Journal:  J Histochem Cytochem       Date:  2007-11-26       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.